Christoph Röllig - Concepedia

Author

Christoph Röllig

University Hospital Carl Gustav Carus ORCID

Also Known As

C Röllig, C. Rollig, C. Röllig, C. Röllig, Christoph RÖllig, Christoph Rollig, Christoph Röllig, Christoph Röllig, K Shirneshan, M Kramer

516

Publications

16.2K

Citations

H-Index

Concepts

All Affiliations

University Hospital Carl Gustav Carus Technische Universität Dresden Heidelberg University Goethe University Frankfurt University Hospital Heidelberg

About

Christoph Röllig is an author at University Hospital Carl Gustav Carus specializing in medicine, oncology, and hematology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	29	47	4K
2	Health Sciences	20	24	2.2K
3	Engineering	2	2	60
4	Public Health	1	1	18
5	Social Sciences	1	1	22

Christoph Röllig

145

Publications

14.4K

Citations

H-Index

Page 1

	Year	Citations
Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN Hartmut Döhner, Andrew H. Wei, Frederick R. Appelbaum, Blood	2022	2.7K
Elotuzumab Therapy for Relapsed or Refractory Multiple Myeloma Sagar Lonial, Meletios Α. Dimopoulos, Antonio Palumbo, New England Journal of Medicine	2015	1.3K
Sorafenib Maintenance After Allogeneic Hematopoietic Stem Cell Transplantation for Acute Myeloid Leukemia With <i>FLT3</i>–Internal Tandem Duplication Mutation (SORMAIN) Andreas Burchert, Gesine Bug, Lea Fritz, Journal of Clinical Oncology	2020	538
Selective inhibition of FLT3 by gilteritinib in relapsed or refractory acute myeloid leukaemia: a multicentre, first-in-human, open-label, phase 1–2 study Alexander E. Perl, Jessica K. Altman, Jörge E. Cortes, The Lancet Oncology Selective InhibitionHematological MalignancyOncologyMedicinePharmacotherapy	2017	484
Addition of sorafenib versus placebo to standard therapy in patients aged 60 years or younger with newly diagnosed acute myeloid leukaemia (SORAML): a multicentre, phase 2, randomised controlled trial Christoph Röllig, Hubert Serve, Andreas Hüttmann, The Lancet Oncology Sorafenib Versus PlaceboHematological MalignancyOncologyMixed-phenotype Acute LeukemiaHematology	2015	395
Azacitidine for treatment of imminent relapse in MDS or AML patients after allogeneic HSCT: results of the RELAZA trial Uwe Platzbecker, Martin Wermke, J. Radke, Leukemia	2011	391
Improved Outcomes With Retinoic Acid and Arsenic Trioxide Compared With Retinoic Acid and Chemotherapy in Non–High-Risk Acute Promyelocytic Leukemia: Final Results of the Randomized Italian-German APL0406 Trial Uwe Platzbecker, Giuseppe Avvisati, Laura Cicconi, Journal of Clinical Oncology	2016	375
Pomalidomide, bortezomib, and dexamethasone for patients with relapsed or refractory multiple myeloma previously treated with lenalidomide (OPTIMISMM): a randomised, open-label, phase 3 trial Paul G. Richardson, Albert Oriol, Meral Beksaç, The Lancet Oncology Hematological MalignancyMedicineHematologyMyeloid NeoplasiaPharmacotherapy	2019	375
Distribution and levels of cell surface expression of CD33 and CD123 in acute myeloid leukemia Armin Ehninger, Michael Krämer, Christoph Röllig, Blood Cancer Journal Mixed-phenotype Acute LeukemiaImmunologyImmunotherapyTumor BiologyMyeloid Neoplasia	2014	344
Measurable residual disease-guided treatment with azacitidine to prevent haematological relapse in patients with myelodysplastic syndrome and acute myeloid leukaemia (RELAZA2): an open-label, multicentre, phase 2 trial Uwe Platzbecker, Jan Moritz Middeke, Katja Sockel, The Lancet Oncology Hematological MalignancyOncologyMixed-phenotype Acute LeukemiaHematologyClinical Trials	2018	341

Page 1